Pneumococcal 13-valent conjugate vaccine (Pfizer)

South Korea's Supreme Court ruled that SK bioscience's PCV13 components do not infringe on Pfizer's patent claims, allowing the company to export vaccine components to high-demand markets.

Sanofi and SK bioscience have initiated global Phase III trials for their 21-valent pneumococcal conjugate vaccine candidate, GBP410, targeting individuals aged six weeks to 17 years.

SK Bioscience has successfully won an appeal against Pfizer's subsidiary Wyeth LLC in a patent dispute over pneumococcal vaccine components exported to Russia for research purposes.

A new £3.2 million Medical Research Council-funded trial, managed by iiCON, will advance the development of a novel vaccine against pneumococcal disease, addressing antibiotic resistance and global health concerns.

A new £3.2 million Medical Research Council-funded trial will advance the development of PnuBioVax, a novel vaccine against pneumococcal disease.